Cabazitaxel (with or without carboplatin) versus 177Lu-PSMA-617 for PSMA-positive metastatic castration-resistant prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase 2 trial compares cabazitaxel chemotherapy (given with or without carboplatin) to the PSMA-targeted radioligand 177Lu-PSMA-617 in patients with PSMA-positive metastatic castration-resistant prostate cancer. Eligibility requires a recent 18F-rhPSMA-7.3 PET scan showing PSMA positivity (including at least one lesion with SUVmax ≥10) or predefined high-risk clinical/genomic features such as visceral metastasis, ≥5 bone lesions, or TP53/PTEN/RB1 alterations. Participants are randomized to one of the treatment arms and followed for imaging responses, clinical outcomes, and safety measures. The design aims to inform optimal sequencing of chemotherapy versus PSMA-directed therapy in this biomarker-selected population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must have histologically or cytologically confirmed adenocarcinoma of prostate
* Evidence of metastatic castrate-resistant prostate cancer that has previously been treated with an androgen receptor pathway inhibitor. Prior docetaxel exposure is recommended but not mandatory. Tissue is not mandatory, but a pathologic report is required at time of enrollment.
* Patients must have a PSMA-positive 18F-rhPSMA-7.3 performed within 12 weeks from C1D1 with ≥1 site with SUVmax ≥10. An alternative PSMA PET tracer is permitted at baseline if performed within 8 weeks prior to randomization.
* Eligible patients have evidence of mCRPC who have progressed on prior novel hormonal agent(s) to include at least one of the following:

  * Baseline PSMA SUVmean \<10 OR
  * ≥1 visceral metastasis OR
  * ≥5 bone metastases OR one of the following (using Next Generation Sequencing on file within 5 years)
  * TP53
  * PTEN
  * mutation.
* Age \> 18 years.
* ECOG performance status of 0 to 2.
* Participants must have adequate organ and marrow function as defined below to be suitable for the randomized treatment outlined in this

  * Absolute neutrophil count \>1000/μL; platelet count \>90 000/μL; hemoglobin \>8.5 g/dL) at screening.
  * Note: Participants must not have received any growth factors within 7 days or blood transfusions within 14 days prior to the hematologic laboratory values obtained at screening).
  * Total bilirubin (TBIL) \<2.5 × the upper limit of normal (ULN) at screening, except participants with documented Gilbert syndrome who must have a TBIL \<3 mg/dL
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 5 ULN at screening
  * Creatinine clearance ≥40 mL/min and/or estimated glomerular filtration rate (eGFR) ≥30
  * Albumin \>30 g/L (3.0 g/dL) at screening
* Participants receiving bisphosphonates or other approved bone-targeting therapy (e.g., denosumab) must be on a stable dose for at least 14 days before the start of study treatment.
* Participants of child-producing potential agree to use highly effective contraceptive methods (i.e., barrier contraception measures such as a male condom with spermicide during intercourse) and avoid sperm donation during the study treatment and for 3 months after the last dose of study treatment. A man is considered to be of child-producing potential, unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. Partners of patients must also practice approved forms of birth control
* Participants must have the ability to understand and the willingness to sign a written informed consent form (ICF).
* Members of all races and ethnic groups are eligible for this trial

Exclusion Criteria:

* Evidence of hormone-sensitive prostate cancer (HSPC)
* Evidence of small cell prostate cancer
* Participants receiving any other investigational agents.
* Diagnosis of another clinically significant malignancy within the previous 2 years other than curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma and other in situ or noninvasive malignancies, as determined by the PI or Co-PI.
* Participants with brain metastases/central nervous system (CNS) disease that are treated prior to enrollment will be allowed in this clinical trial.
* Known or suspected significant hypersensitivity to any components of the formulation used for Cabazitaxel, carboplatin or 177Lu-PSMA-617.
* Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations considered by the Investigator to limit compliance with study requirements.
* Prior treatment toxicities not resolved to ≤ Grade 2 according to NCI CTCAE Version 5.0

Where it's running

• Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Pedro Barata, MD, MSc — Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Institute
• Study coordinator: Pedro Barata, MD, MSc
• Email: Pedro.Barata@UHhospitals.org
• Phone: 216-262-1214

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Actinium (225Ac) PSMA therapy for castration‑resistant prostate cancer after Lutetium

  This trial will test whether an injectable Actinium-225 PSMA treatment can control advanced prostate cancer in men whose disease progressed after Lutetium‑PSMA therapy.

  Recruiting Phase 1/2 University College, London · London · NCT07414940

• Combining carboplatin with docetaxel for advanced prostate cancer treatment

  This study is testing if adding carboplatin to the usual treatment of docetaxel can help people with advanced prostate cancer by slowing down the growth or spread of their disease.

  Recruiting at 14 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 13 other locations · NCT06439225

• JUR-003 in adults with advanced prostate cancer

  This first-in-human study tests JUR-003 to see if it is safe and tolerable and to get an early sense of activity in adults with metastatic or advanced prostate cancer.

  Recruiting at 4 sites Phase 1 TCG Labs Soleil · Grand Rapids, Michigan and 3 other locations · NCT07824349

• JANX013 and JANX007 combo in advanced prostate cancer

  A first-in-human study will test JANX013 together with JANX007 to see if this combination is safe and tolerable in adults with metastatic castration-resistant prostate cancer.

  Recruiting Phase 1 Janux Therapeutics · Nashville, Tennessee · NCT07813637

• SRT-017 radioligand therapy in PSMA-positive metastatic castration-resistant prostate cancer

  This study tests SRT-017 given by IV infusion to men with PSMA-positive metastatic castration-resistant prostate cancer to see if it is safe and tolerable and to gather early signals of anti-tumor activity.

  Recruiting Early Phase 1 Affiliated Hospital of Jiangnan University · Wuxi, Jiangsu · NCT07798778

• Rinzimetostat plus darolutamide in metastatic castration-resistant prostate cancer after abiraterone failure

  This study tests whether adding rinzimetostat to darolutamide helps people with metastatic castration-resistant prostate cancer who previously took abiraterone.

  Recruiting at 15 sites Phase 3 ORIC Pharmaceuticals · Glendale, California and 14 other locations · NCT07723248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.